Walker 256 tumor growth suppression by crotoxin involves formyl peptide receptors and lipoxin a(4)

• Autor(a) principal: Brigatte, Patricia
• Data de Publicação: 2016
• Outros Autores: Faiad, Odair Jorge, Ferreira Nocelli, Roberta Cornelio, Landgraf, Richardt G. [UNIFESP], Palma, Mario Sergio, Cury, Yara, Curi, Rui, Sampaio, Sandra Coccuzzo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1155/2016/2457532; http://repositorio.unifesp.br/handle/11600/49524
• topic: Crotalus-Durissus-Terrificus; Aspirin-Triggered Lipoxins; Arachidonic-Acid; Snake-Venom; Antiangiogenic Therapy; Cell-Proliferation; Lipid Mediators; Analog Suppress; Cobra Venom; Cancer Pain

We investigated the effects of Crotoxin (CTX), the main toxin of South American rattlesnake (Crotalus durissus terrificus) venom, on Walker 256 tumor growth, the pain symptoms associated (hyperalgesia and allodynia), and participation of endogenous lipoxin A(4). Treatment with CTX (s.c.), daily, for 5 days reduced tumor growth at the 5th day after injection of Walker 256 carcinoma cells into the plantar surface of adult rat hind paw. This observation was associated with inhibition of new blood vessel formation and decrease in blood vessel diameter. The treatment with CTX raised plasma concentrations of lipoxin A 4 and its natural analogue 15-epi-LXA(4) 4, an effect mediated by formyl peptide receptors (FPRs). In fact, the treatment with Boc-2, an inhibitor of FPRs, abolished the increase in plasma levels of these mediators triggered by CTX. The blockage of these receptors also abolished the inhibitory action of CTX on tumor growth and blood vessel formation and the decrease in blood vessel diameter. Together, the results herein presented demonstrate that CTX increases plasma concentrations of lipoxin A 4 and 15-epi-LXA 4, which might inhibit both tumor growth and formation of new vessels via FPRs.